Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M


The deal will allow the company to focus its resources on its new drug candidate for cardiogenic shock.

Previous Aurora Capital Partners completes acquisition of Sharps Compliance Corp., taking co. private
Next Middle Eastern food chain Naf Naf opens first Texas location in Frisco